NASDAQ
09.07.26 | 18:16
1,550 US-Dollar
-7,19 % -0,120
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.06. | BeyondSpring Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.06. | BeyondSpring names new CEO, CFO as founder shifts to chairman role | 1 | Investing.com | ||
| 04.06. | BeyondSpring, Inc.: BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value | 204 | GlobeNewswire (Europe) | Dr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer - a structure designed to give... ► Artikel lesen | |
| 02.06. | BeyondSpring reports phase 2 lung cancer trial results at ASCO | 1 | Investing.com | ||
| 02.06. | BeyondSpring, Inc.: BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor ... | 1 | GlobeNewswire (USA) | ||
| BEYONDSPRING Aktie jetzt für 0€ handeln | |||||
| 18.05. | BeyondSpring, Inc.: BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 13.05. | BeyondSpring Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.05. | BeyondSpring Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.04. | BeyondSpring, Inc.: BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs | 1 | GlobeNewswire (USA) | ||
| 30.03. | BeyondSpring, Inc.: BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026 | 3 | GlobeNewswire (USA) | ||
| 25.03. | BeyondSpring Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 25.03. | BeyondSpring, Inc.: BeyondSpring Files 2025 Annual Report on Form 10-K | 1 | GlobeNewswire (USA) | ||
| 25.03. | BeyondSpring, Inc.: BeyondSpring Reports 2025 Year-End Financial Results | 173 | GlobeNewswire (Europe) | Plinabulin (BeyondSpring's Lead Program): Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel demonstrated statistically significant overall survival benefit vs. standard of care... ► Artikel lesen | |
| 25.03. | BeyondSpring Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.12.25 | BeyondSpring, Inc.: BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC | 456 | GlobeNewswire (Europe) | In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 2,260 | -3,83 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Quartals 2026 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN QUARTALS 2026
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA BERICHTET ÜBER... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,211 | +0,96 % | BioNxt treibt das GLP-1-Programm für sublinguales Semaglutid (ODF) voran - nächste Phase der Verabreichungsentwicklung läuft | VANCOUVER, BC / ACCESS Newswire /
6. Juli 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), ein innovatives
Biowissenschaftsunternehmen, das sich... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 9,338 | -4,01 % | BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains? | ||
| ARBUTUS BIOPHARMA | 4,520 | -0,88 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 73,94 | -1,49 % | Chardan: Arrowhead Pharmaceuticals ist Top-Pick im Biotech-Sektor vor wichtigen Daten | ||
| ATAIBECKLEY | 4,740 | +4,41 % | AtaiBeckley Inc.: AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder | 156 patients randomized in multi-center, double-blind, placebo-controlled Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830)AtaiBeckley plans to advance... ► Artikel lesen | |
| ALDEYRA | 1,870 | +1,08 % | Aldeyra appoints Darlene Deptula-Hicks to board of directors | ||
| ABCELLERA BIOLOGICS | 6,400 | +2,73 % | AbCellera Biologics Inc. - 8-K, Current Report | ||
| ADAPTIVE BIOTECHNOLOGIES | 19,105 | +8,30 % | Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses | SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune... ► Artikel lesen | |
| BIOMERIEUX | 70,65 | +2,02 % | BIOMERIEUX: bioMérieux Half-Year Report on Liquidity Agreement as of June 2026 | ||
| BEAM THERAPEUTICS | 35,840 | -2,82 % | BofA bestätigt Kaufempfehlung für Beam Therapeutics nach Schiedsspruch | ||
| AC IMMUNE | 2,220 | +0,68 % | AC Immune SA: AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease | AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease ACI-24 anti-Abeta active immunotherapy generally safe and well tolerated in first three... ► Artikel lesen | |
| 10X GENOMICS | 37,280 | +13,68 % | 10x Genomics, Inc.: 10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group | Acquisition Expands 10x Genomics' Capabilities in Proteomics
PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science... ► Artikel lesen | |
| AGIOS | 37,600 | +0,53 % | Dem Krebs den Stecker ziehen: Agios Pharmaceuticals, Revolution Medicines und Vidac Pharma | Ohne Gesundheit ist alles nichts. In den vergangenen Jahren haben Unternehmen aus den Bereichen Pharma und Biotech bereits große Erfolge erzielt, wenn es darum geht, die Leiden chronisch Kranker oder... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,746 | +5,67 % | BioXcel Therapeutics, Inc. - 8-K, Current Report |
BEYONDSPRING INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,550 Euro und damit -7,19 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BEYONDSPRING INC finden Sie auf Wallstreet Online.